'LigaChemBio Global R&D Day 2025' 행사 시작했습니다.
유튜브 링크를 통해 생중계로 시청 가능하십니다.
https://www.youtube.com/live/V2jHOCY7z7A?si=2hz7mfFWhyLcs3Nw
유튜브 링크를 통해 생중계로 시청 가능하십니다.
https://www.youtube.com/live/V2jHOCY7z7A?si=2hz7mfFWhyLcs3Nw
YouTube
[국문/Korean] LigaChemBio Global R&D DAY 2025
■ 행사명: LigaChemBio Global R&D DAY 2025 / 한국어 (Korean)
■ 일시: 7월 1일 (화) 오전 9:30 - 오후 3:50
■ 행사 일정
09:30 - Opening Remarks
09:50 - The ADC Explosion – the Expanding Landscape of ADCs
10:10 - LigaChem Biosciences' Platform Technology enables differentiated…
■ 일시: 7월 1일 (화) 오전 9:30 - 오후 3:50
■ 행사 일정
09:30 - Opening Remarks
09:50 - The ADC Explosion – the Expanding Landscape of ADCs
10:10 - LigaChem Biosciences' Platform Technology enables differentiated…
❤12🔥1
7월 1일 개최됐던 'LigaChemBio Global R&D Day 2025' 세션별 주요 장표들을 추려서 공유드립니다.
1. 오전 세션
▶️ 김용주 대표 세션:
1. Mid-Term R&D (~2027)
▶️ Steve ACB PL 세션:
2. TROP2 ADC space is active with a majority of topoisomerase inhibiting ADCs
▶️ Robert Lutz IKSUDA CSO 세션:
3. Why another HER2-targeting ADC?
4. Iksuda’s Ongoing Phase 1 Trial with IKS014: Patient Recruitment and Responses
(post-Enhertu 환자 5명 대상 PR 4명, SD 1명으로 DCR 100% + ESMO 2025에서 데이터 추가 업데이트 예정)
5. IKS014 adverse events with incidence ≥ 15% in clinical trial IKS014-01
▶️ Qingmei Shi CStone CMO 세션:
6. CS5001 demonstrates higher ORR as monotherapy in non-Hodgkin lymphoma
7. CS5001 is one of the two leading players in ROR1 ADC global race
8. CS5001 Summary
1. 오전 세션
▶️ 김용주 대표 세션:
1. Mid-Term R&D (~2027)
▶️ Steve ACB PL 세션:
2. TROP2 ADC space is active with a majority of topoisomerase inhibiting ADCs
▶️ Robert Lutz IKSUDA CSO 세션:
3. Why another HER2-targeting ADC?
4. Iksuda’s Ongoing Phase 1 Trial with IKS014: Patient Recruitment and Responses
(post-Enhertu 환자 5명 대상 PR 4명, SD 1명으로 DCR 100% + ESMO 2025에서 데이터 추가 업데이트 예정)
5. IKS014 adverse events with incidence ≥ 15% in clinical trial IKS014-01
▶️ Qingmei Shi CStone CMO 세션:
6. CS5001 demonstrates higher ORR as monotherapy in non-Hodgkin lymphoma
7. CS5001 is one of the two leading players in ROR1 ADC global race
8. CS5001 Summary
❤6👍2🥰2🔥1
2. 오후 세션 (1)
▶️ 정철웅 신약연구소장 세션:
1. Expected IND Timelines
2. Need solution for post-TOP1i payload ADCs
3. Next generation Linker-Payload → Improved Therapeutic Index
▶️ 조병철 다안바이오테라퓨틱스 대표 세션:
4. CEACAM5 as an ADC Target in Colon, Gastric and NSCLC
5. Revisiting the Dogma of CEACAM5-directed ADC
▶️ 장숙경 I-O 센터장 세션:
6. Why Immunotherapy Matters For LCB
7. Leveraging LCB Expertise on Utilizing STING Agonist Immunomodulator
8. LCB39: Differentiated MOA
9. STING Agonist AIC and ADIC: LCB capability
▶️ 정철웅 신약연구소장 세션:
1. Expected IND Timelines
2. Need solution for post-TOP1i payload ADCs
3. Next generation Linker-Payload → Improved Therapeutic Index
▶️ 조병철 다안바이오테라퓨틱스 대표 세션:
4. CEACAM5 as an ADC Target in Colon, Gastric and NSCLC
5. Revisiting the Dogma of CEACAM5-directed ADC
▶️ 장숙경 I-O 센터장 세션:
6. Why Immunotherapy Matters For LCB
7. Leveraging LCB Expertise on Utilizing STING Agonist Immunomodulator
8. LCB39: Differentiated MOA
9. STING Agonist AIC and ADIC: LCB capability
❤8🥰1
3. 오후 세션 (2)
▶️ 채제욱 수석부사장/ACB CEO 세션:
1. OUR VISION 2030 and Evolving Licensing Strategy
2. New Opportunities for Approved ADC Targets with BioBest by Leveraging LCB ADC Platform
3. LCB Tech to Unlock Next Gen ADCs for Validated/Approved Targets : BioBest beyond BioBetter
4. Multi-Asset Strategic Alliance Deal with Global Pharma Positioning ADCs as a Pillar of Future Oncology
▶️ 박세진 사장 세션:
5. Where We Stand on the Path to Vision 2030
6. Financial Outlook
▶️ 채제욱 수석부사장/ACB CEO 세션:
1. OUR VISION 2030 and Evolving Licensing Strategy
2. New Opportunities for Approved ADC Targets with BioBest by Leveraging LCB ADC Platform
3. LCB Tech to Unlock Next Gen ADCs for Validated/Approved Targets : BioBest beyond BioBetter
4. Multi-Asset Strategic Alliance Deal with Global Pharma Positioning ADCs as a Pillar of Future Oncology
▶️ 박세진 사장 세션:
5. Where We Stand on the Path to Vision 2030
6. Financial Outlook
❤11👍5🥰2